{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "bbb2c165-36ee-4436-8d72-33a51ac0e4ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pubmed_parser as pp\n",
    "from getnxml import get_nxml_from_pmcid"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "d538cb8d-4185-4cff-85a2-90e007ae3396",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/Users/shrut/miniforge3/envs/tf/lib/python3.9/site-packages/pubmed_parser/__init__.py'"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pp.__file__"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e7fd59dd-925a-46cd-b124-504785da200e",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = get_nxml_from_pmcid(\"5410135\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "id": "d61550ab-5931-4a81-adeb-a29854feeb8e",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "None\n"
     ]
    }
   ],
   "source": [
    "print(pp.parse_pubmed_table(path))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "58d2f72b-5fc2-4bb6-b264-b73ef4b7b3ac",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'./nxmls/PMC9249242/pone.0270506.nxml'"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "25a65a0b-d579-4f2e-bbb1-8e218b107925",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_paragraph(path, all_paragraph=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "30d77e4d-fe1a-42f7-871d-14468de24e5c",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_references(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "5f7d5d29-4984-4924-bc97-55eb147d0ae0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref001',\n",
       "  'pmid_cited': '2404538',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Heterogeneity of schizophrenia.',\n",
       "  'name': 'MT Tsuang; MJ Lyons; SV Faraone',\n",
       "  'year': '1990',\n",
       "  'journal': 'Br J Psychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref002',\n",
       "  'pmid_cited': '',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Personalized medicine for schizophrenia.',\n",
       "  'name': 'PF Buckley; BJ Miller',\n",
       "  'year': '2017',\n",
       "  'journal': 'npg Schizophr',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref003',\n",
       "  'pmid_cited': '20530008',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Enhanced carbonyl stress in a subpopulation of schizophrenia.',\n",
       "  'name': 'M Arai; H Yuzawa; I Nohara; T Ohnishi; N Obata; Y Iwayama',\n",
       "  'year': '2010',\n",
       "  'journal': 'Arch Gen Psychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref004',\n",
       "  'pmid_cited': '11270668',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Advanced glycation end-products: a review.',\n",
       "  'name': 'R Singh; A Barden; T Mori; L Beilin',\n",
       "  'year': '2001',\n",
       "  'journal': 'Diabetologia',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref005',\n",
       "  'pmid_cited': '29064136',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress.',\n",
       "  'name': 'M Itokawa; M Miyashita; M Arai; T Dan; K Takahashi; T Tokunaga',\n",
       "  'year': '2018',\n",
       "  'journal': 'Psychiatry Clin Neurosci',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref006',\n",
       "  'pmid_cited': '7658823',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genetic basis of schizophrenia.',\n",
       "  'name': 'P McGuffin; M Owen',\n",
       "  'year': '1995',\n",
       "  'journal': 'Lancet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref007',\n",
       "  'pmid_cited': '28987712',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register.',\n",
       "  'name': 'R Hilker; D Helenius; B Fagerlund; A Skytthe; K Christensen; TM Werge',\n",
       "  'year': '2018',\n",
       "  'journal': 'Biol Psychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref008',\n",
       "  'pmid_cited': '19571808',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Common variants conferring risk of schizophrenia.',\n",
       "  'name': 'H Stefansson; RA Ophoff; S Steinberg; OA Andreassen; S Cichon; D Rujescu',\n",
       "  'year': '2009',\n",
       "  'journal': 'Nature',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref009',\n",
       "  'pmid_cited': '25056061',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Biological insights from 108 schizophrenia-associated genetic loci.',\n",
       "  'name': 'S Ripke; BM Neale; A Corvin; JT Walters; K-H Farh; PA Holmans',\n",
       "  'year': '2014',\n",
       "  'journal': 'Nature',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref010',\n",
       "  'pmid_cited': '18668038',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Rare chromosomal deletions and duplications increase risk of schizophrenia.',\n",
       "  'name': 'IS Consortium',\n",
       "  'year': '2008',\n",
       "  'journal': 'Nature',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref011',\n",
       "  'pmid_cited': '27694994',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia.',\n",
       "  'name': 'G Genovese; M Fromer; EA Stahl; DM Ruderfer; K Chambert; M Landén',\n",
       "  'year': '2016',\n",
       "  'journal': 'Nat Neurosci',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref012',\n",
       "  'pmid_cited': '24463508',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'A polygenic burden of rare disruptive mutations in schizophrenia.',\n",
       "  'name': 'SM Purcell; JL Moran; M Fromer; D Ruderfer; N Solovieff; P Roussos',\n",
       "  'year': '2014',\n",
       "  'journal': 'Nature',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref013',\n",
       "  'pmid_cited': '30285260',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genome-wide association study detected novel susceptibility genes for schizophrenia and shared trans-populations/diseases genetic effect.',\n",
       "  'name': 'M Ikeda; A Takahashi; Y Kamatani; Y Momozawa; T Saito; K Kondo',\n",
       "  'year': '2019',\n",
       "  'journal': 'Schizophr Bull',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref014',\n",
       "  'pmid_cited': '18369103',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.',\n",
       "  'name': 'T Walsh; JM McClellan; SE McCarthy; AM Addington; SB Pierce; GM Cooper',\n",
       "  'year': '2008',\n",
       "  'journal': 'Science',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref015',\n",
       "  'pmid_cited': '22424231',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'CNVs: harbingers of a rare variant revolution in psychiatric genetics.',\n",
       "  'name': 'D Malhotra; J Sebat',\n",
       "  'year': '2012',\n",
       "  'journal': 'Cell',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref016',\n",
       "  'pmid_cited': '27869829',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects.',\n",
       "  'name': 'CR Marshall; DP Howrigan; D Merico; B Thiruvahindrapuram; W Wu; DS Greer',\n",
       "  'year': '2017',\n",
       "  'journal': 'Nat Genet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref017',\n",
       "  'pmid_cited': '30208311',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights.',\n",
       "  'name': 'I Kushima; B Aleksic; M Nakatochi; T Shimamura; T Okada; Y Uno',\n",
       "  'year': '2018',\n",
       "  'journal': 'Cell Rep',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref018',\n",
       "  'pmid_cited': '8637877',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.',\n",
       "  'name': 'T Miyata; S Taneda; R Kawai; Y Ueda; S Horiuchi; M Hara',\n",
       "  'year': '1996',\n",
       "  'journal': 'Proc Natl Acad Sci USA',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref019',\n",
       "  'pmid_cited': '27932244',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Transcriptional response to mitochondrial protease IMMP2L knockdown in human primary astrocytes.',\n",
       "  'name': 'A Gokoolparsadh; Z Fang; N Braidy; P Lin; CJ Pardy; V Eapen',\n",
       "  'year': '2017',\n",
       "  'journal': 'Biochem Biophys Res Commun',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref020',\n",
       "  'pmid_cited': '29486958',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Whole genome sequencing of 91 multiplex schizophrenia families reveals increased burden of rare, exonic copy number variation in schizophrenia probands and genetic heterogeneity.',\n",
       "  'name': 'FF Khan; PE Melton; NS McCarthy; B Morar; J Blangero; EK Moses',\n",
       "  'year': '2018',\n",
       "  'journal': 'Schizophr Res',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref021',\n",
       "  'pmid_cited': '22883433',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genome-wide association study implicates HLA-C* 01: 02 as a risk factor at the major histocompatibility complex locus in schizophrenia.',\n",
       "  'name': 'ISG Consortium',\n",
       "  'year': '2012',\n",
       "  'journal': 'Biol Psychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref022',\n",
       "  'pmid_cited': '26198764',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genome‐wide association study of schizophrenia in Ashkenazi Jews.',\n",
       "  'name': 'FS Goes; J McGrath; D Avramopoulos; P Wolyniec; M Pirooznia; I Ruczinski',\n",
       "  'year': '2015',\n",
       "  'journal': 'Am J Med Genet B Neuropsychiatr Genet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref023',\n",
       "  'pmid_cited': '19401682',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L–DOCK4 gene region in autism susceptibility.',\n",
       "  'name': 'E Maestrini; A Pagnamenta; J Lamb; E Bacchelli; N Sykes; I Sousa',\n",
       "  'year': '2010',\n",
       "  'journal': 'Mol Psychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref024',\n",
       "  'pmid_cited': '29152845',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Association of IMMP2L deletions with autism spectrum disorder: A trio family study and meta‐analysis.',\n",
       "  'name': 'Y Zhang; Y Liu; M Zarrei; W Tong; R Dong; Y Wang',\n",
       "  'year': '2018',\n",
       "  'journal': 'Am J Med Genet B Neuropsychiatr Genet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref025',\n",
       "  'pmid_cited': '29788020',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genomic deletion involving the IMMP2L gene in two cases of autism spectrum disorder.',\n",
       "  'name': 'F Baldan; C Gnan; A Franzoni; L Ferino; L Allegri; N Passon',\n",
       "  'year': '2018',\n",
       "  'journal': 'Cytogenet Genome Res',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref026',\n",
       "  'pmid_cited': '19546859',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes.',\n",
       "  'name': 'J Elia; X Gai; H Xie; J Perin; E Geiger; J Glessner',\n",
       "  'year': '2010',\n",
       "  'journal': 'Mol Psychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref027',\n",
       "  'pmid_cited': '25478008',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Interstitial 7q31. 1 copy number variations disrupting IMMP2L gene are associated with a wide spectrum of neurodevelopmental disorders.',\n",
       "  'name': 'S Gimelli; V Capra; M Di Rocco; M Leoni; M Mirabelli-Badenier; MC Schiaffino',\n",
       "  'year': '2014',\n",
       "  'journal': 'Mol Cytogenet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref028',\n",
       "  'pmid_cited': '22410579',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'The genetics of Tourette syndrome.',\n",
       "  'name': 'H Deng; K Gao; J Jankovic',\n",
       "  'year': '2012',\n",
       "  'journal': 'Nat Rev Neurol',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref029',\n",
       "  'pmid_cited': '11254443',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associated with Tourette syndrome.',\n",
       "  'name': 'E Petek; C Windpassinger; JB Vincent; J Cheung; AP Boright; SW Scherer',\n",
       "  'year': '2001',\n",
       "  'journal': 'Am J Hum Genet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref030',\n",
       "  'pmid_cited': '24549057',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome.',\n",
       "  'name': 'B Bertelsen; L Melchior; LR Jensen; C Groth; B Glenthøj; R Rizzo',\n",
       "  'year': '2014',\n",
       "  'journal': 'Eur J Hum Genet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref031',\n",
       "  'pmid_cited': '',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Association of a schizophrenia risk variant with memory function.',\n",
       "  'name': 'S Maul; B Konte; A Hartmann; I Giegling; D Rujescu',\n",
       "  'year': '2020',\n",
       "  'journal': 'Pharmacopsychiatry',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref032',\n",
       "  'pmid_cited': '21136665',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia.',\n",
       "  'name': 'D Clark; I Dedova; S Cordwell; I Matsumoto',\n",
       "  'year': '2007',\n",
       "  'journal': 'Proteomics Clin Appl',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref033',\n",
       "  'pmid_cited': '31233820',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'First behavioural assessment of a novel Immp2l knockdown mouse model with relevance for Gilles de la Tourette syndrome and Autism spectrum disorder.',\n",
       "  'name': 'F Kreilaus; R Chesworth; V Eapen; R Clarke; T Karl',\n",
       "  'year': '2019',\n",
       "  'journal': 'Behav Brain Res',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref034',\n",
       "  'pmid_cited': '21332923',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Mitochondrial peptidase IMMP2L mutation causes early onset of age‐associated disorders and impairs adult stem cell self‐renewal.',\n",
       "  'name': 'SK George; Y Jiao; CE Bishop; B Lu',\n",
       "  'year': '2011',\n",
       "  'journal': 'Aging Cell',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref035',\n",
       "  'pmid_cited': '21824519',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Deficiency in the inner mitochondrial membrane peptidase 2-like (Immp21) gene increases ischemic brain damage and impairs mitochondrial function.',\n",
       "  'name': 'Y Ma; SL Mehta; B Lu; PA Li',\n",
       "  'year': '2011',\n",
       "  'journal': 'Neurobiol Dis',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref036',\n",
       "  'pmid_cited': '26616244',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'The Immp2l mutation causes age‐dependent degeneration of cerebellar granule neurons prevented by antioxidant treatment.',\n",
       "  'name': 'C Liu; X Li; B Lu',\n",
       "  'year': '2016',\n",
       "  'journal': 'Aging Cell',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref037',\n",
       "  'pmid_cited': '17051205',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.',\n",
       "  'name': 'MT Lin; MF Beal',\n",
       "  'year': '2006',\n",
       "  'journal': 'Nature',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref038',\n",
       "  'pmid_cited': '19348707',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genetics of autism spectrum disorders.',\n",
       "  'name': 'RA Kumar; SL Christian',\n",
       "  'year': '2009',\n",
       "  'journal': 'Curr Neurol Neurosci Rep',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref039',\n",
       "  'pmid_cited': '28007608',\n",
       "  'doi_cited': '',\n",
       "  'article_title': '16p13 microduplication without CREBBP involvement: Moving toward a phenotype delineation.',\n",
       "  'name': 'C Ciaccio; A Tucci; G Scuvera; M Estienne; S Esposito; D Milani',\n",
       "  'year': '2017',\n",
       "  'journal': 'Eur J Med Genet',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref040',\n",
       "  'pmid_cited': '27283361',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genetic dissection of mammalian ERAD through comparative haploid and CRISPR forward genetic screens.',\n",
       "  'name': 'RT Timms; SA Menzies; IA Tchasovnikarova; LC Christensen; JC Williamson; R Antrobus',\n",
       "  'year': '2016',\n",
       "  'journal': 'Nat Commun',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref041',\n",
       "  'pmid_cited': '18682727',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'Genome-wide survey and expression profiling of CCCH-zinc finger family reveals a functional module in macrophage activation.',\n",
       "  'name': 'J Liang; W Song; G Tromp; PE Kolattukudy; M Fu',\n",
       "  'year': '2008',\n",
       "  'journal': 'PloS One',\n",
       "  'journal_type': 'journal'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'ref_id': 'pone.0270506.ref042',\n",
       "  'pmid_cited': '27990022',\n",
       "  'doi_cited': '',\n",
       "  'article_title': 'RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins.',\n",
       "  'name': 'M Fu; PJ Blackshear',\n",
       "  'year': '2017',\n",
       "  'journal': 'Nat Rev Immunol',\n",
       "  'journal_type': 'journal'}]"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dicts_out"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "8fc100bd-11e8-45fe-b353-e86c37f992d1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Introduction',\n",
       "  'text': 'Schizophrenia (SCZ) is a devastating psychiatric disorder with a typical onset time during adolescence or early adulthood and requires lifelong antipsychotic treatment after diagnosis. Despite intensive research efforts, treatments for SCZ remain limited to dopamine receptor D2 and 5-hydroxytryptamine receptor 2A antagonists. Novel therapeutic targets with proven efficacy have not been developed for decades.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref001',\n",
       "   'pone.0270506.ref002',\n",
       "   'pone.0270506.ref003',\n",
       "   'pone.0270506.ref004',\n",
       "   'pone.0270506.ref005'],\n",
       "  'section': 'Introduction',\n",
       "  'text': 'Considering the clinical heterogeneity of SCZ [1], one of the most promising strategies for identifying novel therapeutic targets to develop personalized medicine is determining a specific treatment for each SCZ subtype defined by biological profiling, such as metabolome or transcriptome analysis [2]. We previously identified a subpopulation of SCZ characterized by high plasma pentosidine (PEN-SCZ) [3]. Pentosidine, an advanced glycation end product, is a biological marker of glycation and oxidative stress [4]. Based on these findings, we conducted a 24-week, open-label design clinical trial of pyridoxal in patients with SCZ, partially confirming its efficacy (UMIN000006398) [5]. Of the 10 participants, two patients showed marked improvements in psychotic symptoms, and one patient with a GLO1 frameshift mutation showed considerable improvement accompanied by reduced plasma pentosidine levels. Hence, we sought to identify novel therapeutic target for PEN-SCZ by clarifying the causative factors through investigating genetic factors that confer the pathophysiology of PEN-SCZ.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref006',\n",
       "   'pone.0270506.ref007',\n",
       "   'pone.0270506.ref008',\n",
       "   'pone.0270506.ref012',\n",
       "   'pone.0270506.ref009',\n",
       "   'pone.0270506.ref013'],\n",
       "  'section': 'Introduction',\n",
       "  'text': 'The etiology of SCZ has a profound genetic component [6], with the heritability of this disease reported as 60–80% [7]. Considerable progress has been made in determining the genetic architecture of SCZ. Accumulated evidence suggests that both common and rare variants are involved in the SCZ etiology [8–12]. The Psychiatric Genomic Consortium (PGC) performed a large genome-wide association study of SCZ, in which 108 risk loci, located at genes related to synaptic networks, the immune system, and mitochondrial metabolism were found to be associated with SCZ [9]. Recently, Ikeda et al. confirmed these findings in a trans-populational manner in European, East Asian, and Japanese populations [13].'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref014',\n",
       "   'pone.0270506.ref015',\n",
       "   'pone.0270506.ref009',\n",
       "   'pone.0270506.ref016',\n",
       "   'pone.0270506.ref016',\n",
       "   'pone.0270506.ref017'],\n",
       "  'section': 'Introduction',\n",
       "  'text': 'An elevated burden of rare copy number variants (CNVs) among patients with SCZ has also been well-established [14, 15]. Although common single-nucleotide polymorphisms have small individual effects (odds ratio (OR) <1.2) [9], several rare CNVs have been shown to have a much stronger impact on risk (OR <67.7) [16]. The PGC CNV Analysis Group successfully overcame the limited statistical power of small sample sizes and detected six novel loci, including Xq28, 7q11.21, and 8q22.2, in the largest genome-wide CNV study (N = 41,321) [16]. In an Asian population, Kushima et al. confirmed the increased burden of rare (≤1%) exonic CNVs using the largest sample size of the Japanese population (2,458 SCZ cases and 2,095 controls) [17].'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref017'],\n",
       "  'section': 'Introduction',\n",
       "  'text': 'In this study, we investigated rare (≤1%) CNVs associated with PEN-SCZ by assessing genome-wide CNV data [17] and measuring plasma pentosidine between a PEN-SCZ group and non-PEN-SCZ group.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref017', 'pone.0270506.t001'],\n",
       "  'section': 'Participants',\n",
       "  'text': 'For both genetic and biochemical analyses, 185 unrelated, ethnically Japanese patients with SCZ and identified to harbor rare (≤1%) CNVs in the previous study [17] were assessed in this study. All patients were recruited from the Department of Neuropsychiatry, Tokyo Metropolitan Matsuzawa Hospital, Takatsuki Hospital, Takatsuki Clinic, and RIKEN Brain Science Institute located near Tokyo. Patients were diagnosed based on the DSM-IV (American Psychiatric Association) criteria for SCZ or schizoaffective disorder by the consensus of at least two experienced psychiatrists. Patients with a history of drug addiction or alcohol abuse/dependence were excluded from the study. Patients with diabetes mellitus or chronic renal disease as a comorbidity with SCZ were also excluded from the study, as these diseases may affect plasma pentosidine levels. This study was approved by the research ethics committee of the participating institutes, and written informed consent was obtained from all subjects prior to obtaining their medical records. The present study was performed in accordance with the Declaration of Helsinki. The demographics are presented in Table 1.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': '',\n",
       "  'text': 'aSchizophrenia with accumulation of plasma pentosidine.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': '',\n",
       "  'text': 'bSchizophrenia without accumulation of plasma pentosidine.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': '',\n",
       "  'text': 'cStandard deviation.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': '',\n",
       "  'text': 'dCut off value; 55.2.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref017',\n",
       "   'pone.0270506.ref017',\n",
       "   'pone.0270506.ref017'],\n",
       "  'section': 'CNV analysis',\n",
       "  'text': 'CNV calling was performed as described previously [17]. Briefly, NimbleGen 720K Whole-Genome Tiling arrays (probe spacing 2.5\\u2009kb; Roche NimbleGen, Madison, WI, USA) were used for genome-wide CNV screening. CNV calls were made using Nexus Copy Number software v. 7.5 (BioDiscovery, El Segundo, CA, USA) with a hidden Markov model-based approach. All genomic locations are listed in the National Center for Biotechnology Information build 36/UCSC hg18 coordinates, and Lift Genome Annotations: https://genome.ucsc.edu/cgi-bin/hgLiftOver was used to convert the genomic location from March 2006 (NCBI36/hg18) to December 2013 (GRCh38/hg38). All analyses were conducted based on gene annotation from GENCODE version 21 (http://www.gencodegenes.org/releases/21.html) [17]. Randomly selected CNVs were validated using quantitative real-time PCR combined with TaqMan copy number assays (Applied Biosystems, Foster City, CA, USA) [17]. CNVs identified in the database of healthy controls were removed using the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/).'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref003',\n",
       "   'pone.0270506.ref005',\n",
       "   'pone.0270506.ref018'],\n",
       "  'section': 'Measurement of plasma pentosidine',\n",
       "  'text': 'The plasma concentration of pentosidine was measured by high-performance liquid chromatography; 55.2 ng/mL was set as the cut-off to define the PEN-SCZ and non-PEN-SCZ groups as described previously [3, 5, 18].'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Clinical characteristics of shared CNV carriers in PEN-SCZ',\n",
       "  'text': 'The clinical characteristics of PEN-SCZ cases with shared CNVs obtained through assessment of medical records included the existence of developmental delay, autistic features, epilepsy, age at onset, psychiatric symptoms, mood symptoms, antipsychotic treatment, and presence of negative symptoms.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref017'],\n",
       "  'section': 'Statistical analysis',\n",
       "  'text': 'For demographic data, the average age, age of onset, plasma pentosidine levels, and average of chlorpromazine equivalent doses were compared by Student’s t-test (two-tailed). For CNV analysis, the average of total CNV sizes and total number of genes within CNVs were assessed by Student’s t-test. To evaluate the association between PEN-SCZ and shared exonic deletions, one-sided Fisher’s exact tests were used. If no variants were found in the two-by-two table, the OR was calculated after a 0 cell correction to reduce bias as reported previously [17].'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.g001', 'pone.0270506.t002'],\n",
       "  'section': 'Exonic deletions among patients with PEN-SCZ',\n",
       "  'text': 'We investigated rare (≤1%) CNVs associated with SCZ in patients who presented with increased levels of plasma pentosidine, a biological marker for glycation and oxidative stress (PEN-SCZ), to identify novel drug targets for treating PEN-SCZ. A total of 185 patients with SCZ harboring rare CNVs was separated into two groups based on their plasma pentosidine levels (cut-off value; 55.2 ng/mL): 94 patients with PEN-SCZ and 91 patients with non-PEN-SCZ (Fig 1). The PEN-SCZ group harbored shared CNVs such as deletion in 7q31.1 and duplication in 16p13.13, which were not observed in control or non-PEN-SCZ subjects (Table 2).'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Deletions in IMMP2L across various neuropsychiatric disorders.',\n",
       "  'text': 'A summary of the findings, including those of previous studies and this study, on IMMP2L deletions across neuropsychiatric disorders, is presented. Exonic deletion in IMMP2L tends to span from exons 1 to 3 across neuropsychiatric disorders including ASD, GTS, ADHD, and OCD. PEN-SCZ-related deletions found in this study were also restricted to exons 1–3. ASD: autism spectrum disorder; ADHD: attention-deficit hyperactivity disorder; BPD: bipolar disorder; GTS: Gilles de la Tourette syndrome; OCD: obsessive-compulsive disorder; PEN-SCZ: schizophrenia with accumulation of pentosidine in the plasma.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': '',\n",
       "  'text': 'ASD: autism spectrum disorder; CNV: copy number variation; PEN: pentosidine; SCZ: schizophrenia; Del: deletion'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.t002',\n",
       "   'pone.0270506.t002',\n",
       "   'pone.0270506.g002',\n",
       "   'pone.0270506.t002'],\n",
       "  'section': 'Exonic deletions among patients with PEN-SCZ',\n",
       "  'text': 'Regarding the CNV in 7q31.1, although it was not significant, deletions in IMMP2L exons 2 and 3 were detected in three patients with PEN-SCZ whose plasma pentosidine levels were 83.91, 82.96, and 64.45 ng/mL, respectively (p = 0.135, Table 2). Patients I and II with PEN-SCZ harbored the same deletion spanning IMMP2L exons 1–3, with a length of 186,957 bp from chromosome (Chr.) 7: 111,431,428 to 111,618,385. Patient III with PEN-SCZ had a deletion in IMMP2L exons 2 and 3 (Table 2). One non-PEN-SCZ subject had a microdeletion in 7q31.1, which included an IMMP2L intronic region (patient IV, Fig 2). Duplication of 16p13.13, another shared CNV in three patients with PEN-SCZ, included exons of TXNDC11 and ZC3H7A, which encode the thioredoxin domain containing 11 and CCCH-type zinc finger containing 7A, respectively (Table 2).'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Clinical manifestation of schizophrenia with enhanced glycation stress harboring deletion in IMMP2L at 7q31.1.',\n",
       "  'text': 'We observed a shared exonic deletion in IMMP2L exons 2 and 3 in three patients with SCZ presenting with accumulation of pentosidine in the plasma, although it was not significant. Patients with SCZ harboring deletions spanning exons 2 and 3 in IMMP2L showed autistic features, such as limited social communication skills and repetitive, obsessive behavior in addition to psychosis.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Exonic deletions among patients with PEN-SCZ',\n",
       "  'text': 'Among the three genes disrupted by the shared CNVs, IMMP2L was a recurrent SCZ risk gene found in the previous SCZ genome-wide association study conducted by the PGC. Hence, we assessed whether the clinical features were shared among the three patients with PEN-SCZ harboring exonic deletions in IMMP2L, although its association was not significant, possibly because of the small sample size.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.t002'],\n",
       "  'section': 'Clinical characteristics of patients with PEN-SCZ harboring exonic deletions in IMMP2L',\n",
       "  'text': 'According to clinical records, shared clinical characteristics among the patients with PEN-SCZ were observed. For example, in addition to psychosis, the three patients harboring a deletion in IMMP2L exons 2 and 3 had autistic features (Table 2). Patient I was diagnosed with autism spectrum disorder (ASD) in addition to SCZ, and her social communication skills were extremely limited since childhood. Patient III also showed limited social skills since childhood and is currently considered to be a SCZ subtype for which most prominent symptoms were negative symptoms. Patient II also showed a limited social communication capability with repetitive behaviors since childhood.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Discussion',\n",
       "  'text': 'In this study, we observed the shared 7q31.1 deletion spanning exons 2 and 3 in IMMP2L, known as one of the SCZ risk genes, among a subtype of SCZ with enhanced glycation and oxidative stress (PEN-SCZ), presenting with additional ASD phenotypes or limited social capability, although the association was not significant. Interestingly, deletion or duplication in other exons or introns of IMMP2L did not affect the plasma pentosidine level. Another CNV, a duplication at 16p13.13, was identified as a candidate for a shared genetic background in other PEN-SCZ cases, disrupting TXNDC11 and ZC3H7A.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref019',\n",
       "   'pone.0270506.ref009',\n",
       "   'pone.0270506.ref013',\n",
       "   'pone.0270506.ref020',\n",
       "   'pone.0270506.ref022',\n",
       "   'pone.0270506.ref023',\n",
       "   'pone.0270506.ref025',\n",
       "   'pone.0270506.ref026',\n",
       "   'pone.0270506.ref027',\n",
       "   'pone.0270506.ref028',\n",
       "   'pone.0270506.ref030',\n",
       "   'pone.0270506.g001',\n",
       "   'pone.0270506.g001',\n",
       "   'pone.0270506.s001'],\n",
       "  'section': 'IMMP2L deletions and neuropsychiatric disorders',\n",
       "  'text': 'IMMP2L, inner mitochondrial membrane peptidase 2-like, is a mitochondrial enzyme critical for glycolysis as the main pathway using glucose to respond to energy demands in the brain. IMMP2L knockdown in primary astrocytes leads to dysregulation of genes involved in brain development [19]. CNVs or genomic variations disrupting IMMP2L have been reported across neurodevelopmental psychiatric disorders, including SCZ [9, 13, 20–22], ASD [23–25], attention-deficit hyperactivity disorder (ADHD) [26, 27], and Gilles de la Tourette syndrome (GTS) [28–30]. We summarized past and present findings on IMMP2L deletions across neuropsychiatric disorders (Fig 1); the results suggested that behavioral phenotypes vary depending on the exons disrupted by CNVs in IMMP2L. Interestingly, exonic deletions in IMMP2L tend to span from exons 1 to 3 across various neuropsychiatric disorders, including ASD, GTS, ADHD, and OCD but excluding bipolar disorder. PEN-SCZ-related deletions found in this study also appeared to be restricted to exons 1 to 3 (Fig 1). To investigate the effect of the CNV deletion on IMMP2L in patients with SCZ, we examined possibility if any proteins could be produced from the allele of IMMP2L with the exon deletions. We found no open reading frames with enough length, as the lengths of exon 2, exon 3, and their totals are not multiple of three (that is, 137nt, 104nt, and 241nt). To assess if any compensation effect happened from the allele with no deletions, we measured IMMP2L mRNA in whole blood cells from patients with SCZ and a control subject. Our data indicated that the IMMP2L full-length form tended to be lower in patients with CNV deletion than that in a healthy individual without the CNV deletion, suggesting no compensation at the level of RNA (S1 Fig). Furthermore, in order to evaluate the possibility of loss-of-function and gain-of-function, we conducted a western blot experiment on the C-terminal antibody of IMMP2L protein. However, due to the lack of detectable IMMP2L expression in PBMC, definite truncated-form were not observed in a wild-type control subject.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref009',\n",
       "   'pone.0270506.ref013',\n",
       "   'pone.0270506.ref031',\n",
       "   'pone.0270506.ref029',\n",
       "   'pone.0270506.ref032'],\n",
       "  'section': 'IMMP2L and schizophrenia',\n",
       "  'text': 'Notably, IMMP2L is an SCZ risk loci gene identified by the PGC in the previous SCZ-genome-wide association study (rank 15, p = 3.034 × 10−13) [9]. Ikeda et al. confirmed the trans-populational association between IMMP2L rs214467 and SCZ (p = 4.74 × 10−11) [13]. Moreover, association analysis of the 108 SCZ risk loci and cognitive functions revealed the most significant associations between rs13240464 within IMMP2L and “delayed recall” and “visual memory [31]. Taken together with our results from a pilot study with a small sample size, both common and rare IMMP2L variants may be involved in the SCZ etiology. Previous studies revealed that IMMP2L exon 6 transcripts were expressed across brain regions, including in the hippocampus, temporal lobe, and thalamus [29]. These transcripts are relevant to cognitive function and sensory gating and have been shown to be disrupted in patients with SCZ; however, other exons have not been fully investigated. In postmortem brain studies of SCZ, expression of glycerol-3-phosphate dehydrogenase 2, the substrate for IMMP2L, has been reported to be altered in the anterior cingulate cortex [32]. Although we did not observe a significant association between rare exonic deletions in IMMP2L and PEN-SCZ, given our small sample size, IMMP2L is a candidate therapeutic target in PEN-SCZ, particularly for the improvement of memory function; however, this should be evaluated in a larger sample size.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref025',\n",
       "   'pone.0270506.ref028',\n",
       "   'pone.0270506.ref029',\n",
       "   'pone.0270506.g002',\n",
       "   'pone.0270506.ref025',\n",
       "   'pone.0270506.ref024',\n",
       "   'pone.0270506.g001',\n",
       "   'pone.0270506.ref029'],\n",
       "  'section': 'Clinical characteristics of IMMP2L deletion carriers in PEN-SCZ',\n",
       "  'text': 'Patients harboring the 7q31.1 deletion, which includes IMMP2L, have been reported to present some repetitive behavioral phenotypes and/or obsessive-compulsive symptoms observed in ASD [25], obsessive-compulsive disorder, and GTS [28, 29]. ASD is characterized by reduced reciprocal social interaction, an impaired ability to communicate, a narrow range of interests, and repetitive behaviors. Baldan et al. identified two patients with ASD who harbored deletions in IMMP2L from exons 1 to 3 and in introns (Fig 2) [25]. Zhang et al. genotyped 100 trio families that included patients with ASD in a Han Chinese population and identified three cases carrying rare IMMP2L exonic deletions [24]. In a Danish cohort study investigating CNVs in 188 unrelated patients with Tourette syndrome, seven patients were found to have IMMP2L deletions, which were also restricted to exons 1–3 (Fig 1) [29].'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.t002',\n",
       "   'pone.0270506.ref033',\n",
       "   'pone.0270506.ref033'],\n",
       "  'section': 'Clinical characteristics of IMMP2L deletion carriers in PEN-SCZ',\n",
       "  'text': 'In this study, PEN-SCZ patients I and II, who carried deletions in IMMP2L exons 1–3, presented with additional autistic features, including limited social communication skills in addition to psychosis (Table 2). Interestingly, a previous animal study demonstrated that IMMP2L knockout mice displayed behavioral changes in social interactions linked to both limited social skills in ASD and negative symptoms in SCZ [33]. Limited social skills in ASD may be broadly linked to negative symptoms in SCZ, in terms of their biological aspects associated with possibly impaired IMMP2L function. Supporting this notion, animal studies demonstrated dysfunction of the dopamine system in IMMP2L knockout mice [33]; therefore, an IMMP2L modulator may improve both the autistic features and limited social communication capacity.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref034',\n",
       "   'pone.0270506.ref035',\n",
       "   'pone.0270506.s001',\n",
       "   'pone.0270506.ref035'],\n",
       "  'section': 'IMMP2L and glycation/oxidative stress',\n",
       "  'text': 'A mutant mouse model of IMMP2L has been reported to show elevated mitochondrial reactive oxygen species and an increased plasma carbonyl content, both of which reflect glycation and oxidative stress [34]. IMMP2L deficiency in the brain mitochondria has been shown to critically affect normal brain function [35]. In our reverse transcription-PCR experiment, gene expression levels of IMMP2L were lower in IMMP2L-deficient cases compared to wild type (S1 Fig). Immp2l deficiency has been shown to enhance production of superoxide and to have damaging effect on the mitochondrial function that may lead enhanced glycation stress [35].'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref036',\n",
       "   'pone.0270506.ref037',\n",
       "   'pone.0270506.ref036'],\n",
       "  'section': 'IMMP2L and glycation/oxidative stress',\n",
       "  'text': 'Interestingly, IMMP2L mutant mice developed neuronal degeneration in an age-dependent manner [36]. Mitochondrial reactive oxygen species have been implicated in age-related disorders, such as neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease [37]. Mitochondria-targeting antioxidant skQ1 has been shown to rescue age-dependent neurodegeneration in an IMMP2L mutant mouse model [36]. Studies are needed to determine whether the SCZ behavioral phenotype can be rescued by skQ1 in a mouse model of SCZ with enhanced glycation/oxidative stress.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'IMMP2L and glycation/oxidative stress',\n",
       "  'text': 'In the present study, we aimed to clarify the molecular mechanisms that cause the accumulation of pentosidine. In four cases with CNV deletion, a subsequent pentosidine accumulation was expected, but it could not be confirmed in a patient IV. This observation suggests that an unknown IMMP2L independent molecular pathway was involved in the pentosidine alteration. Due to difficulty in re-recruiting a patient IV, we were unable to conduct further analysis. In the future, a higher number of patients must be considered for further investigation and the link between the IMMP2L deficiency and the mitochondrial dysfunctions or an accelerated reactive oxygen species and whether mechanisms for pentosidine linked to phenomenon occurs in patients with IMMP2L CNV should be clarified.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref038',\n",
       "   'pone.0270506.ref039',\n",
       "   'pone.0270506.ref040',\n",
       "   'pone.0270506.ref040'],\n",
       "  'section': 'TXNDC11 and ZC3H7A',\n",
       "  'text': 'TXNDC11 and ZC3H7A were also found to be affected by rare CNVs at 16p13.13. The 16p13.13 duplication has never been linked with SCZ; however, it has been reported in patients diagnosed with ASD [38], intellectual disability, developmental delay, facial asymmetry, growth deficiency, and several congenital anomalies [39]. TXNDC11 encodes a thioredoxin domain containing 11, known as an endoplasmic reticulum-resident thioredoxin domain protein [40]. Thioredoxin is an intrinsic antioxidant system and TXNDC11 may act as a redox regulator involved in DUOX protein folding [40]. In redox homeostasis, TXNDX11 may be involved in the accumulation of plasma pentosidine in PEN-SCZ.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': ['pone.0270506.ref041', 'pone.0270506.ref042'],\n",
       "  'section': 'TXNDC11 and ZC3H7A',\n",
       "  'text': 'ZC3H7A encodes zinc finger CCCH-type containing 7A and has been shown to be a crucial regulator of immune responses [41] through the regulation of cytokine production, immune cell activation, immune homeostasis, and antiviral responses [42]. Although genetic associations between SCZ and ZC3H7A have never been reported, further investigation of the relationship between ZC3H7A and the pathophysiology of SCZ would be of interest in terms of immune system disturbance, which has also been strongly implicated in SCZ.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Limitations',\n",
       "  'text': 'A major strength of this study is that it was an integrative study investigating CNVs with metabolomes, which provided insights into the pathophysiology of PEN-SCZ and led to the identification of a shared genetic background for this biological subtype. However, there were some limitations. First, the sample size was small; thus, further research of a larger sample size is needed to examine the involvement of IMMP2L in the etiology of PEN-SCZ. Second, as we only investigated rare CNVs as a genetic background, other genetic and epigenetic factors that account for enhanced glycation and oxidative stress must be investigated to clarify the whole picture of PEN-SCZ etiology. Third, patients with PEN-SCZ were significantly older and taking more medications than non-PEN-SCZ subjects. It is possible that pentosidine elevates as a function of age or medication in this population.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'Conclusions',\n",
       "  'text': 'We identified shared exonic deletion in exons 2 and 3 in IMMP2L, a recurrent SCZ risk locus gene, among three PEN-SCZ cases presenting with additional ASD phenotypes or limited social capability. Future research of a larger sample size is warranted to validate the association, as it was not significant possibly because of the small sample size. Experimental validation of the involvement of IMMP2L exonic deletion in plasma pentosidine accumulation should also be examined. Additionally, accumulation of genetic data linked with omics and phenotypic profiles would improve the definition of the biological subtypes of SCZ.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'RT-PCR analysis of IMMP2L levels.',\n",
       "  'text': 'As shown in RT-PCR experiments, we confirmed that expression levels were lower in IMMP2L-deficient cases compared to wild type.'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': 'RT-PCR analysis of IMMP2L levels.',\n",
       "  'text': '(TIF)'},\n",
       " {'pmc': '9249242',\n",
       "  'pmid': '35776734',\n",
       "  'reference_ids': [],\n",
       "  'section': '',\n",
       "  'text': 'Click here for additional data file.'}]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dicts_out"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "fe369804-6661-4a97-9504-52f38f7a631a",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_paragraph(path, all_paragraph=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "d069c877-db5b-4a4b-9b3c-63d0c12c1ff4",
   "metadata": {},
   "outputs": [],
   "source": [
    "curr_section = None\n",
    "text = \"\"\n",
    "for d in dicts_out:\n",
    "    if d['section'] == curr_section:\n",
    "        text = text + d['text'] + '\\n\\n'\n",
    "    else:\n",
    "        text = text + d['section'] + '\\n\\n' + d['text'] + '\\n\\n'\n",
    "        curr_section = d['section']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "f0b579be-eb07-49db-b5a7-c7dce3310ac7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Introduction\n",
      "\n",
      "Schizophrenia (SCZ) is a devastating psychiatric disorder with a typical onset time during adolescence or early adulthood and requires lifelong antipsychotic treatment after diagnosis. Despite intensive research efforts, treatments for SCZ remain limited to dopamine receptor D2 and 5-hydroxytryptamine receptor 2A antagonists. Novel therapeutic targets with proven efficacy have not been developed for decades.\n",
      "\n",
      "Considering the clinical heterogeneity of SCZ [1], one of the most promising strategies for identifying novel therapeutic targets to develop personalized medicine is determining a specific treatment for each SCZ subtype defined by biological profiling, such as metabolome or transcriptome analysis [2]. We previously identified a subpopulation of SCZ characterized by high plasma pentosidine (PEN-SCZ) [3]. Pentosidine, an advanced glycation end product, is a biological marker of glycation and oxidative stress [4]. Based on these findings, we conducted a 24-week, open-label design clinical trial of pyridoxal in patients with SCZ, partially confirming its efficacy (UMIN000006398) [5]. Of the 10 participants, two patients showed marked improvements in psychotic symptoms, and one patient with a GLO1 frameshift mutation showed considerable improvement accompanied by reduced plasma pentosidine levels. Hence, we sought to identify novel therapeutic target for PEN-SCZ by clarifying the causative factors through investigating genetic factors that confer the pathophysiology of PEN-SCZ.\n",
      "\n",
      "The etiology of SCZ has a profound genetic component [6], with the heritability of this disease reported as 60–80% [7]. Considerable progress has been made in determining the genetic architecture of SCZ. Accumulated evidence suggests that both common and rare variants are involved in the SCZ etiology [8–12]. The Psychiatric Genomic Consortium (PGC) performed a large genome-wide association study of SCZ, in which 108 risk loci, located at genes related to synaptic networks, the immune system, and mitochondrial metabolism were found to be associated with SCZ [9]. Recently, Ikeda et al. confirmed these findings in a trans-populational manner in European, East Asian, and Japanese populations [13].\n",
      "\n",
      "An elevated burden of rare copy number variants (CNVs) among patients with SCZ has also been well-established [14, 15]. Although common single-nucleotide polymorphisms have small individual effects (odds ratio (OR) <1.2) [9], several rare CNVs have been shown to have a much stronger impact on risk (OR <67.7) [16]. The PGC CNV Analysis Group successfully overcame the limited statistical power of small sample sizes and detected six novel loci, including Xq28, 7q11.21, and 8q22.2, in the largest genome-wide CNV study (N = 41,321) [16]. In an Asian population, Kushima et al. confirmed the increased burden of rare (≤1%) exonic CNVs using the largest sample size of the Japanese population (2,458 SCZ cases and 2,095 controls) [17].\n",
      "\n",
      "In this study, we investigated rare (≤1%) CNVs associated with PEN-SCZ by assessing genome-wide CNV data [17] and measuring plasma pentosidine between a PEN-SCZ group and non-PEN-SCZ group.\n",
      "\n",
      "Participants\n",
      "\n",
      "For both genetic and biochemical analyses, 185 unrelated, ethnically Japanese patients with SCZ and identified to harbor rare (≤1%) CNVs in the previous study [17] were assessed in this study. All patients were recruited from the Department of Neuropsychiatry, Tokyo Metropolitan Matsuzawa Hospital, Takatsuki Hospital, Takatsuki Clinic, and RIKEN Brain Science Institute located near Tokyo. Patients were diagnosed based on the DSM-IV (American Psychiatric Association) criteria for SCZ or schizoaffective disorder by the consensus of at least two experienced psychiatrists. Patients with a history of drug addiction or alcohol abuse/dependence were excluded from the study. Patients with diabetes mellitus or chronic renal disease as a comorbidity with SCZ were also excluded from the study, as these diseases may affect plasma pentosidine levels. This study was approved by the research ethics committee of the participating institutes, and written informed consent was obtained from all subjects prior to obtaining their medical records. The present study was performed in accordance with the Declaration of Helsinki. The demographics are presented in Table 1.\n",
      "\n",
      "\n",
      "\n",
      "aSchizophrenia with accumulation of plasma pentosidine.\n",
      "\n",
      "bSchizophrenia without accumulation of plasma pentosidine.\n",
      "\n",
      "cStandard deviation.\n",
      "\n",
      "dCut off value; 55.2.\n",
      "\n",
      "CNV analysis\n",
      "\n",
      "CNV calling was performed as described previously [17]. Briefly, NimbleGen 720K Whole-Genome Tiling arrays (probe spacing 2.5 kb; Roche NimbleGen, Madison, WI, USA) were used for genome-wide CNV screening. CNV calls were made using Nexus Copy Number software v. 7.5 (BioDiscovery, El Segundo, CA, USA) with a hidden Markov model-based approach. All genomic locations are listed in the National Center for Biotechnology Information build 36/UCSC hg18 coordinates, and Lift Genome Annotations: https://genome.ucsc.edu/cgi-bin/hgLiftOver was used to convert the genomic location from March 2006 (NCBI36/hg18) to December 2013 (GRCh38/hg38). All analyses were conducted based on gene annotation from GENCODE version 21 (http://www.gencodegenes.org/releases/21.html) [17]. Randomly selected CNVs were validated using quantitative real-time PCR combined with TaqMan copy number assays (Applied Biosystems, Foster City, CA, USA) [17]. CNVs identified in the database of healthy controls were removed using the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/).\n",
      "\n",
      "Measurement of plasma pentosidine\n",
      "\n",
      "The plasma concentration of pentosidine was measured by high-performance liquid chromatography; 55.2 ng/mL was set as the cut-off to define the PEN-SCZ and non-PEN-SCZ groups as described previously [3, 5, 18].\n",
      "\n",
      "Clinical characteristics of shared CNV carriers in PEN-SCZ\n",
      "\n",
      "The clinical characteristics of PEN-SCZ cases with shared CNVs obtained through assessment of medical records included the existence of developmental delay, autistic features, epilepsy, age at onset, psychiatric symptoms, mood symptoms, antipsychotic treatment, and presence of negative symptoms.\n",
      "\n",
      "Statistical analysis\n",
      "\n",
      "For demographic data, the average age, age of onset, plasma pentosidine levels, and average of chlorpromazine equivalent doses were compared by Student’s t-test (two-tailed). For CNV analysis, the average of total CNV sizes and total number of genes within CNVs were assessed by Student’s t-test. To evaluate the association between PEN-SCZ and shared exonic deletions, one-sided Fisher’s exact tests were used. If no variants were found in the two-by-two table, the OR was calculated after a 0 cell correction to reduce bias as reported previously [17].\n",
      "\n",
      "Exonic deletions among patients with PEN-SCZ\n",
      "\n",
      "We investigated rare (≤1%) CNVs associated with SCZ in patients who presented with increased levels of plasma pentosidine, a biological marker for glycation and oxidative stress (PEN-SCZ), to identify novel drug targets for treating PEN-SCZ. A total of 185 patients with SCZ harboring rare CNVs was separated into two groups based on their plasma pentosidine levels (cut-off value; 55.2 ng/mL): 94 patients with PEN-SCZ and 91 patients with non-PEN-SCZ (Fig 1). The PEN-SCZ group harbored shared CNVs such as deletion in 7q31.1 and duplication in 16p13.13, which were not observed in control or non-PEN-SCZ subjects (Table 2).\n",
      "\n",
      "Deletions in IMMP2L across various neuropsychiatric disorders.\n",
      "\n",
      "A summary of the findings, including those of previous studies and this study, on IMMP2L deletions across neuropsychiatric disorders, is presented. Exonic deletion in IMMP2L tends to span from exons 1 to 3 across neuropsychiatric disorders including ASD, GTS, ADHD, and OCD. PEN-SCZ-related deletions found in this study were also restricted to exons 1–3. ASD: autism spectrum disorder; ADHD: attention-deficit hyperactivity disorder; BPD: bipolar disorder; GTS: Gilles de la Tourette syndrome; OCD: obsessive-compulsive disorder; PEN-SCZ: schizophrenia with accumulation of pentosidine in the plasma.\n",
      "\n",
      "\n",
      "\n",
      "ASD: autism spectrum disorder; CNV: copy number variation; PEN: pentosidine; SCZ: schizophrenia; Del: deletion\n",
      "\n",
      "Exonic deletions among patients with PEN-SCZ\n",
      "\n",
      "Regarding the CNV in 7q31.1, although it was not significant, deletions in IMMP2L exons 2 and 3 were detected in three patients with PEN-SCZ whose plasma pentosidine levels were 83.91, 82.96, and 64.45 ng/mL, respectively (p = 0.135, Table 2). Patients I and II with PEN-SCZ harbored the same deletion spanning IMMP2L exons 1–3, with a length of 186,957 bp from chromosome (Chr.) 7: 111,431,428 to 111,618,385. Patient III with PEN-SCZ had a deletion in IMMP2L exons 2 and 3 (Table 2). One non-PEN-SCZ subject had a microdeletion in 7q31.1, which included an IMMP2L intronic region (patient IV, Fig 2). Duplication of 16p13.13, another shared CNV in three patients with PEN-SCZ, included exons of TXNDC11 and ZC3H7A, which encode the thioredoxin domain containing 11 and CCCH-type zinc finger containing 7A, respectively (Table 2).\n",
      "\n",
      "Clinical manifestation of schizophrenia with enhanced glycation stress harboring deletion in IMMP2L at 7q31.1.\n",
      "\n",
      "We observed a shared exonic deletion in IMMP2L exons 2 and 3 in three patients with SCZ presenting with accumulation of pentosidine in the plasma, although it was not significant. Patients with SCZ harboring deletions spanning exons 2 and 3 in IMMP2L showed autistic features, such as limited social communication skills and repetitive, obsessive behavior in addition to psychosis.\n",
      "\n",
      "Exonic deletions among patients with PEN-SCZ\n",
      "\n",
      "Among the three genes disrupted by the shared CNVs, IMMP2L was a recurrent SCZ risk gene found in the previous SCZ genome-wide association study conducted by the PGC. Hence, we assessed whether the clinical features were shared among the three patients with PEN-SCZ harboring exonic deletions in IMMP2L, although its association was not significant, possibly because of the small sample size.\n",
      "\n",
      "Clinical characteristics of patients with PEN-SCZ harboring exonic deletions in IMMP2L\n",
      "\n",
      "According to clinical records, shared clinical characteristics among the patients with PEN-SCZ were observed. For example, in addition to psychosis, the three patients harboring a deletion in IMMP2L exons 2 and 3 had autistic features (Table 2). Patient I was diagnosed with autism spectrum disorder (ASD) in addition to SCZ, and her social communication skills were extremely limited since childhood. Patient III also showed limited social skills since childhood and is currently considered to be a SCZ subtype for which most prominent symptoms were negative symptoms. Patient II also showed a limited social communication capability with repetitive behaviors since childhood.\n",
      "\n",
      "Discussion\n",
      "\n",
      "In this study, we observed the shared 7q31.1 deletion spanning exons 2 and 3 in IMMP2L, known as one of the SCZ risk genes, among a subtype of SCZ with enhanced glycation and oxidative stress (PEN-SCZ), presenting with additional ASD phenotypes or limited social capability, although the association was not significant. Interestingly, deletion or duplication in other exons or introns of IMMP2L did not affect the plasma pentosidine level. Another CNV, a duplication at 16p13.13, was identified as a candidate for a shared genetic background in other PEN-SCZ cases, disrupting TXNDC11 and ZC3H7A.\n",
      "\n",
      "IMMP2L deletions and neuropsychiatric disorders\n",
      "\n",
      "IMMP2L, inner mitochondrial membrane peptidase 2-like, is a mitochondrial enzyme critical for glycolysis as the main pathway using glucose to respond to energy demands in the brain. IMMP2L knockdown in primary astrocytes leads to dysregulation of genes involved in brain development [19]. CNVs or genomic variations disrupting IMMP2L have been reported across neurodevelopmental psychiatric disorders, including SCZ [9, 13, 20–22], ASD [23–25], attention-deficit hyperactivity disorder (ADHD) [26, 27], and Gilles de la Tourette syndrome (GTS) [28–30]. We summarized past and present findings on IMMP2L deletions across neuropsychiatric disorders (Fig 1); the results suggested that behavioral phenotypes vary depending on the exons disrupted by CNVs in IMMP2L. Interestingly, exonic deletions in IMMP2L tend to span from exons 1 to 3 across various neuropsychiatric disorders, including ASD, GTS, ADHD, and OCD but excluding bipolar disorder. PEN-SCZ-related deletions found in this study also appeared to be restricted to exons 1 to 3 (Fig 1). To investigate the effect of the CNV deletion on IMMP2L in patients with SCZ, we examined possibility if any proteins could be produced from the allele of IMMP2L with the exon deletions. We found no open reading frames with enough length, as the lengths of exon 2, exon 3, and their totals are not multiple of three (that is, 137nt, 104nt, and 241nt). To assess if any compensation effect happened from the allele with no deletions, we measured IMMP2L mRNA in whole blood cells from patients with SCZ and a control subject. Our data indicated that the IMMP2L full-length form tended to be lower in patients with CNV deletion than that in a healthy individual without the CNV deletion, suggesting no compensation at the level of RNA (S1 Fig). Furthermore, in order to evaluate the possibility of loss-of-function and gain-of-function, we conducted a western blot experiment on the C-terminal antibody of IMMP2L protein. However, due to the lack of detectable IMMP2L expression in PBMC, definite truncated-form were not observed in a wild-type control subject.\n",
      "\n",
      "IMMP2L and schizophrenia\n",
      "\n",
      "Notably, IMMP2L is an SCZ risk loci gene identified by the PGC in the previous SCZ-genome-wide association study (rank 15, p = 3.034 × 10−13) [9]. Ikeda et al. confirmed the trans-populational association between IMMP2L rs214467 and SCZ (p = 4.74 × 10−11) [13]. Moreover, association analysis of the 108 SCZ risk loci and cognitive functions revealed the most significant associations between rs13240464 within IMMP2L and “delayed recall” and “visual memory [31]. Taken together with our results from a pilot study with a small sample size, both common and rare IMMP2L variants may be involved in the SCZ etiology. Previous studies revealed that IMMP2L exon 6 transcripts were expressed across brain regions, including in the hippocampus, temporal lobe, and thalamus [29]. These transcripts are relevant to cognitive function and sensory gating and have been shown to be disrupted in patients with SCZ; however, other exons have not been fully investigated. In postmortem brain studies of SCZ, expression of glycerol-3-phosphate dehydrogenase 2, the substrate for IMMP2L, has been reported to be altered in the anterior cingulate cortex [32]. Although we did not observe a significant association between rare exonic deletions in IMMP2L and PEN-SCZ, given our small sample size, IMMP2L is a candidate therapeutic target in PEN-SCZ, particularly for the improvement of memory function; however, this should be evaluated in a larger sample size.\n",
      "\n",
      "Clinical characteristics of IMMP2L deletion carriers in PEN-SCZ\n",
      "\n",
      "Patients harboring the 7q31.1 deletion, which includes IMMP2L, have been reported to present some repetitive behavioral phenotypes and/or obsessive-compulsive symptoms observed in ASD [25], obsessive-compulsive disorder, and GTS [28, 29]. ASD is characterized by reduced reciprocal social interaction, an impaired ability to communicate, a narrow range of interests, and repetitive behaviors. Baldan et al. identified two patients with ASD who harbored deletions in IMMP2L from exons 1 to 3 and in introns (Fig 2) [25]. Zhang et al. genotyped 100 trio families that included patients with ASD in a Han Chinese population and identified three cases carrying rare IMMP2L exonic deletions [24]. In a Danish cohort study investigating CNVs in 188 unrelated patients with Tourette syndrome, seven patients were found to have IMMP2L deletions, which were also restricted to exons 1–3 (Fig 1) [29].\n",
      "\n",
      "In this study, PEN-SCZ patients I and II, who carried deletions in IMMP2L exons 1–3, presented with additional autistic features, including limited social communication skills in addition to psychosis (Table 2). Interestingly, a previous animal study demonstrated that IMMP2L knockout mice displayed behavioral changes in social interactions linked to both limited social skills in ASD and negative symptoms in SCZ [33]. Limited social skills in ASD may be broadly linked to negative symptoms in SCZ, in terms of their biological aspects associated with possibly impaired IMMP2L function. Supporting this notion, animal studies demonstrated dysfunction of the dopamine system in IMMP2L knockout mice [33]; therefore, an IMMP2L modulator may improve both the autistic features and limited social communication capacity.\n",
      "\n",
      "IMMP2L and glycation/oxidative stress\n",
      "\n",
      "A mutant mouse model of IMMP2L has been reported to show elevated mitochondrial reactive oxygen species and an increased plasma carbonyl content, both of which reflect glycation and oxidative stress [34]. IMMP2L deficiency in the brain mitochondria has been shown to critically affect normal brain function [35]. In our reverse transcription-PCR experiment, gene expression levels of IMMP2L were lower in IMMP2L-deficient cases compared to wild type (S1 Fig). Immp2l deficiency has been shown to enhance production of superoxide and to have damaging effect on the mitochondrial function that may lead enhanced glycation stress [35].\n",
      "\n",
      "Interestingly, IMMP2L mutant mice developed neuronal degeneration in an age-dependent manner [36]. Mitochondrial reactive oxygen species have been implicated in age-related disorders, such as neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease [37]. Mitochondria-targeting antioxidant skQ1 has been shown to rescue age-dependent neurodegeneration in an IMMP2L mutant mouse model [36]. Studies are needed to determine whether the SCZ behavioral phenotype can be rescued by skQ1 in a mouse model of SCZ with enhanced glycation/oxidative stress.\n",
      "\n",
      "In the present study, we aimed to clarify the molecular mechanisms that cause the accumulation of pentosidine. In four cases with CNV deletion, a subsequent pentosidine accumulation was expected, but it could not be confirmed in a patient IV. This observation suggests that an unknown IMMP2L independent molecular pathway was involved in the pentosidine alteration. Due to difficulty in re-recruiting a patient IV, we were unable to conduct further analysis. In the future, a higher number of patients must be considered for further investigation and the link between the IMMP2L deficiency and the mitochondrial dysfunctions or an accelerated reactive oxygen species and whether mechanisms for pentosidine linked to phenomenon occurs in patients with IMMP2L CNV should be clarified.\n",
      "\n",
      "TXNDC11 and ZC3H7A\n",
      "\n",
      "TXNDC11 and ZC3H7A were also found to be affected by rare CNVs at 16p13.13. The 16p13.13 duplication has never been linked with SCZ; however, it has been reported in patients diagnosed with ASD [38], intellectual disability, developmental delay, facial asymmetry, growth deficiency, and several congenital anomalies [39]. TXNDC11 encodes a thioredoxin domain containing 11, known as an endoplasmic reticulum-resident thioredoxin domain protein [40]. Thioredoxin is an intrinsic antioxidant system and TXNDC11 may act as a redox regulator involved in DUOX protein folding [40]. In redox homeostasis, TXNDX11 may be involved in the accumulation of plasma pentosidine in PEN-SCZ.\n",
      "\n",
      "ZC3H7A encodes zinc finger CCCH-type containing 7A and has been shown to be a crucial regulator of immune responses [41] through the regulation of cytokine production, immune cell activation, immune homeostasis, and antiviral responses [42]. Although genetic associations between SCZ and ZC3H7A have never been reported, further investigation of the relationship between ZC3H7A and the pathophysiology of SCZ would be of interest in terms of immune system disturbance, which has also been strongly implicated in SCZ.\n",
      "\n",
      "Limitations\n",
      "\n",
      "A major strength of this study is that it was an integrative study investigating CNVs with metabolomes, which provided insights into the pathophysiology of PEN-SCZ and led to the identification of a shared genetic background for this biological subtype. However, there were some limitations. First, the sample size was small; thus, further research of a larger sample size is needed to examine the involvement of IMMP2L in the etiology of PEN-SCZ. Second, as we only investigated rare CNVs as a genetic background, other genetic and epigenetic factors that account for enhanced glycation and oxidative stress must be investigated to clarify the whole picture of PEN-SCZ etiology. Third, patients with PEN-SCZ were significantly older and taking more medications than non-PEN-SCZ subjects. It is possible that pentosidine elevates as a function of age or medication in this population.\n",
      "\n",
      "Conclusions\n",
      "\n",
      "We identified shared exonic deletion in exons 2 and 3 in IMMP2L, a recurrent SCZ risk locus gene, among three PEN-SCZ cases presenting with additional ASD phenotypes or limited social capability. Future research of a larger sample size is warranted to validate the association, as it was not significant possibly because of the small sample size. Experimental validation of the involvement of IMMP2L exonic deletion in plasma pentosidine accumulation should also be examined. Additionally, accumulation of genetic data linked with omics and phenotypic profiles would improve the definition of the biological subtypes of SCZ.\n",
      "\n",
      "RT-PCR analysis of IMMP2L levels.\n",
      "\n",
      "As shown in RT-PCR experiments, we confirmed that expression levels were lower in IMMP2L-deficient cases compared to wild type.\n",
      "\n",
      "(TIF)\n",
      "\n",
      "\n",
      "\n",
      "Click here for additional data file.\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "e9590c4a-47df-46b6-a949-2338bfabddef",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('PMC9249242.txt', 'w') as f:\n",
    "    f.write(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "d3157d8a-5293-48b0-9991-620f563b4f90",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = get_nxml_from_pmcid(\"9249242\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "ba59741b-d424-4f9a-ab0f-6acbc53639eb",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_table(path, return_xml=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "52e18a2a-6371-4e7d-a38d-214f03407095",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "7d0e0e74-563b-4f7b-8fd8-b4d1e32b7c09",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'./nxmls/PMC9249242/pone.0270506.nxml'"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "beaa7656-2a62-467e-9619-b1591dc7f740",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_caption(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "1b34d2d6-6e7c-49da-8c1f-bf8ddb951b7d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'fig_caption': 'Deletions in IMMP2L across various neuropsychiatric disorders. A summary of the findings, including those of previous studies and this study, on IMMP2L deletions across neuropsychiatric disorders, is presented. Exonic deletion in IMMP2L tends to span from exons 1 to 3 across neuropsychiatric disorders including ASD, GTS, ADHD, and OCD. PEN-SCZ-related deletions found in this study were also restricted to exons 1–3. ASD: autism spectrum disorder; ADHD: attention-deficit hyperactivity disorder; BPD: bipolar disorder; GTS: Gilles de la Tourette syndrome; OCD: obsessive-compulsive disorder; PEN-SCZ: schizophrenia with accumulation of pentosidine in the plasma.',\n",
       "  'fig_id': 'pone.0270506.g001',\n",
       "  'fig_label': 'Fig 1',\n",
       "  'graphic_ref': 'pone.0270506.g001'},\n",
       " {'pmid': '35776734',\n",
       "  'pmc': '9249242',\n",
       "  'fig_caption': 'Clinical manifestation of schizophrenia with enhanced glycation stress harboring deletion in IMMP2L at 7q31.1. We observed a shared exonic deletion in IMMP2L exons 2 and 3 in three patients with SCZ presenting with accumulation of pentosidine in the plasma, although it was not significant. Patients with SCZ harboring deletions spanning exons 2 and 3 in IMMP2L showed autistic features, such as limited social communication skills and repetitive, obsessive behavior in addition to psychosis.',\n",
       "  'fig_id': 'pone.0270506.g002',\n",
       "  'fig_label': 'Fig 2',\n",
       "  'graphic_ref': 'pone.0270506.g002'}]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dicts_out"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "2b3fee2d-fec2-4abf-89c1-6b56fb12b29c",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pubmed_parser as pp\n",
    "dicts_out = pp.parse_pubmed_table(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "id": "3f1d0589-1028-4af5-8a89-68f749267662",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "id": "124cc8f5-3d56-465b-a8e2-685463583424",
   "metadata": {},
   "outputs": [],
   "source": [
    "path = get_nxml_from_pmcid(\"5410135\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "id": "1eb2f967-ca4f-4416-a703-b26d2fe53923",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_table(path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "id": "cbda227c-cedb-451c-bd30-b5246f5be99b",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "28d16bf5-46ae-439c-b070-5858cd79934d",
   "metadata": {},
   "outputs": [],
   "source": [
    "dicts_out = pp.parse_pubmed_paragraph(path, all_paragraph=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "66130a93-8656-4ceb-9c49-0e1c357664f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "d1 = pp.parse_pubmed_xml(path, nxml=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "c4fd95f2-4009-462f-9fd1-6c648646ffa0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'full_title': 'The Effect of Interactions of Single Nucleotide Polymorphisms of APOA1/APOC3 with Food Group Intakes on the Risk of Metabolic Syndrome',\n",
       " 'abstract': 'Background: The aim of this study was to examine the interaction of dietary food groups and genetic variants of APOA1/APOC3, relative to Metabolic Syndrome (MetS) risk in adults. Methods: In this matched nested case-control study, 414 MetS subjects and 414 controls were selected from among participants of Tehran Lipid and Glucose Study. Dietary intake was assessed with the use of a valid and reliable semi-quantitative food frequency questionnaire. Single Nucleotide Polymorphisms (SNPs), APOA1 (rs670, −75G>A and rs5069, +83C>T/APOC3 rs5128 C3238>G) were genotyped by the conventional polymerase chain reaction and restriction fragment length polymorphism. Results: The mean (SD) of age was 40.7 (13) and 41.2 (13) years in male cases and controls versus 44.0 (11) and 44.0 (12) years in female case and controls. A significant interaction between intake quartiles of the sugar group and APOA1 combined group (GA+AA/CT+TT) SNPs was found; The ORs for these genotype carriers were (1, 0.44, 0.36, 0.23; P trend<0.001) in quartiles of intake, relative to other combined genotypes (P interaction=0.02). MetS risk appeared to be increased significantly in higher quartiles of sweet beverages and fish intakes in the GA+AA/CT+TT/CC genotypes of APOA1/APOC3 SNPs, compared to other genotypes (P interaction=0.01). The combined effect of genotypes of APOC3/APOA1 showed further decrease in MetS risk in higher quartiles of sugar group intakes (OR: 1, 0.24, 0.26, 0.14, P trend=0.001) relative to other combinations (P interaction=0.008). Conclusion: Results obtained demonstrate that some dietary food groups (sugar, fish, and sweet beverages) modulate the effect of APOA1/APOC3 SNPs in relation to MetS risk.',\n",
       " 'journal': 'Avicenna Journal of Medical Biotechnology',\n",
       " 'pmid': '28496949',\n",
       " 'pmc': '5410135',\n",
       " 'doi': '',\n",
       " 'publisher_id': 'ajmb-9-94',\n",
       " 'author_list': [['Hosseini-Esfahani', 'Firoozeh', 'AFF1'],\n",
       "  ['Mirmiran', 'Parvin', 'AFF1'],\n",
       "  ['Mirmiran', 'Parvin', 'AFF2'],\n",
       "  ['Daneshpour', 'Maryam S.', 'AFF3'],\n",
       "  ['Mottaghi', 'Azadeh', 'AFF1'],\n",
       "  ['Azizi', 'Fereidoun', 'AFF4']],\n",
       " 'affiliation_list': [['AFF1',\n",
       "   'Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran'],\n",
       "  ['AFF2',\n",
       "   'Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran'],\n",
       "  ['AFF3',\n",
       "   'Cellular Molecular and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran'],\n",
       "  ['AFF4',\n",
       "   'Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran']],\n",
       " 'publication_year': '2017',\n",
       " 'publication_date': '01-01-2017',\n",
       " 'subjects': 'Original Article',\n",
       " 'coi_statement': 'Conflict of Interest\\nNone of the authors has any conflict of interest to declare.'}"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "d1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2fa2e8c8-3e36-4830-8595-909a72313fdf",
   "metadata": {},
   "outputs": [],
   "source": [
    "f\\d\\"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "75099dd5-6500-4e0c-acf8-2ee7d889386d",
   "metadata": {},
   "outputs": [],
   "source": [
    "text = \"\"\n",
    "text = text + d1[\"full_title\"] + \"\\n\\n\"\n",
    "text = text + \"Abstract\" + \"\\n\\n\" + d1['abstract'] + \"\\n\\n\"\n",
    "\n",
    "curr_section = None\n",
    "\n",
    "sections = {}\n",
    "i = 0\n",
    "for d in dicts_out:\n",
    "    curr_sec = d['section']\n",
    "    if curr_sec in sections:\n",
    "        sections[curr_sec][1] = sections[curr_sec][1] + d['text'] + '\\n\\n'\n",
    "    else:\n",
    "        sections[curr_sec] = [i, \"\"]\n",
    "        i += 1\n",
    "        sections[curr_sec][1] = sections[curr_sec][1] + d['text'] + '\\n\\n'\n",
    "        # curr_section = d['section']\n",
    "\n",
    "sections_list = list(sections.items())\n",
    "sections_list.sort(key=lambda x : x[1][0])\n",
    "\n",
    "for sec_name, [_, sec_text] in sections_list:\n",
    "    text += sec_name + \"\\n\\n\" + sec_text \n",
    "    \n",
    "if 'coi_statement' in d1:\n",
    "    text += d1['coi_statement']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "0c461566-780b-4fac-a50b-b6a55e3c2a35",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The Effect of Interactions of Single Nucleotide Polymorphisms of APOA1/APOC3 with Food Group Intakes on the Risk of Metabolic Syndrome\n",
      "\n",
      "Abstract\n",
      "\n",
      "Background: The aim of this study was to examine the interaction of dietary food groups and genetic variants of APOA1/APOC3, relative to Metabolic Syndrome (MetS) risk in adults. Methods: In this matched nested case-control study, 414 MetS subjects and 414 controls were selected from among participants of Tehran Lipid and Glucose Study. Dietary intake was assessed with the use of a valid and reliable semi-quantitative food frequency questionnaire. Single Nucleotide Polymorphisms (SNPs), APOA1 (rs670, −75G>A and rs5069, +83C>T/APOC3 rs5128 C3238>G) were genotyped by the conventional polymerase chain reaction and restriction fragment length polymorphism. Results: The mean (SD) of age was 40.7 (13) and 41.2 (13) years in male cases and controls versus 44.0 (11) and 44.0 (12) years in female case and controls. A significant interaction between intake quartiles of the sugar group and APOA1 combined group (GA+AA/CT+TT) SNPs was found; The ORs for these genotype carriers were (1, 0.44, 0.36, 0.23; P trend<0.001) in quartiles of intake, relative to other combined genotypes (P interaction=0.02). MetS risk appeared to be increased significantly in higher quartiles of sweet beverages and fish intakes in the GA+AA/CT+TT/CC genotypes of APOA1/APOC3 SNPs, compared to other genotypes (P interaction=0.01). The combined effect of genotypes of APOC3/APOA1 showed further decrease in MetS risk in higher quartiles of sugar group intakes (OR: 1, 0.24, 0.26, 0.14, P trend=0.001) relative to other combinations (P interaction=0.008). Conclusion: Results obtained demonstrate that some dietary food groups (sugar, fish, and sweet beverages) modulate the effect of APOA1/APOC3 SNPs in relation to MetS risk.\n",
      "\n",
      "Introduction\n",
      "\n",
      "The worldwide increase in the incidence of the Metabolic Syndrome (MetS) and diabetes mellitus over the last few decades is a salient example of how the interaction between lifestyle and genotype can dramatically impact health. Some of good reasons for this interaction are the familial nature of MetS , the obvious difference in the prevalence of MetS within various racial groups  and the different rates of MetS prevalence among monozygotic twins . Interactions between genes and diet play important roles in the development of MetS, although contribution of each per se can be different . For example, in a study conducted on 303 elderly pairs of twins, it was observed that glucose intolerance, obesity and low concentrations of High Density Lipoprotein Cholesterol (HDL-C) are significantly higher among monozygotic twins than among dizygotic twins, indicating the outstanding role of genetics in this area. On the other hand, in the case of insulin, triglyceride levels and blood pressure, the role of environmental factors including diet were more important than genetics .\n",
      "\n",
      "Decreased HDL-C concentration is a hallmark of the dyslipidemic profile associated with the development of MetS . Apolipoprotein A1 (APOA1) is one of the major structural and functional protein constituents of HDL-C and an in vivo activator of Lecithin-Cholesterol- Acyltransferase (LCAT). An inverse relationship has been reported between apoA1 and HDL-C and CVD in general populations . The gene encoding APOA1 is highly polymorphic and several Single Nucleotide Polymorphisms (SNPs) have been identified in the apoA1 gene located on the long arm of chromosome 11, in association with plasma lipid and lipoprotein concentrations. Among these, a common G/A substitution located at –75 bp upstream from the apoA1 transcription start site (rs670) and a C/T substitution at position +83 bp (rs5069) from the first intron were reported to differentially affect apoA1 expression . Some studies have shown that allele A is strongly associated with higher HDL-C and APOA1 . Moreover, MetS risk was exacerbated among individuals who had high intakes of fat (>35% energy) and monoun-saturated fat (>14% energy) and GG homozygote for the APOA1 rs670 . The relevance of APOC3 to human triglyceride (TG) rich lipoprotein metabolism comes primarily from genetic studies, which have consistently shown associations between the APOC3 locus and TG concentration. APOC3 inhibits lipolysis of very low-density lipoproteins via non-competitive inhibition of lipoprotein lipase and hepatic triglyceride lipase activity, and by interfering with lipoprotein binding to glycosaminoglycans on cell membranes . Of several variants within APOC3, a transversion from C to G in the 3′ untranslated region (3′UTR) of exon 4 results in an rs5128 polymorphism (also known as SstI, sacI, 3238C>G or 3175C>G) . One study showed that higher levels of Low Density Lipoprotein Cholesterol (LDL-C) and total cholesterol were associated with a higher saturated fatty acid intake for the G allele of APOA1 G-75A (rs670) and higher LDL-C was associated with a higher saturated fat and total fat intake for allele C of APOC3 3238C>G (rs5128) . Due to the fact that until now, no study has investigated interactions between food groups and APOA1/APOC3 SNPs, the main goal of present study was to examine the interaction of dietary food groups and some genetic variants of APOA1/APOC3, relative to MetS risk in adults.\n",
      "\n",
      "Study population\n",
      "\n",
      "This nested case-control study was a part of the Tehran Lipid and Glucose Study (TLGS), an ongoing population based cohort study being conducted to determine the risk factors of non-communicable diseases on a sample of residents of district 13 of Tehran, the capital of Iran. The baseline examination survey was conducted from 1999 to 2001 in 15005 subjects, aged ≥3 years, and follow-up examinations have been conducted every 3 years (2002–2005; 2006–2008; 2008–2011) to update health related measurements of baseline characteristics and to identify any newly developed diseases .\n",
      "\n",
      "Of 11001 and 9807 individuals, aged≥18 years, who participated in baseline and second follow-up surveys respectively, 5280 were excluded because of having MetS at either baseline or second follow-up survey. In the current study, 503 cases were randomly selected from among participants who developed MetS at the third (n=918) and fourth (n=827) follow-up surveys. After excluding individuals with a history of cardiovascular events, weight loss or gain >5 kg in the last 6 months, pregnant or lactating women, or those taking any CVD/anticoagulant/steroid or hormonal medication (n=20), 483 cases were included in the study. Controls were defined as participants with ≤1 MetS components at the time that the corresponding case developed MetS. Each case was individually pair matched with a control, randomly by age (±5 years) and sex. After excluding cases/controls lacking DNA purification in the range of 1.7<A260/A280<2(n=108), and those whose reported energy intake divided by the predicted energy intake did not qualify for the ±3 SD range (n=30), finally, 828 (414 pairs) MetS and matched controls remained for the analysis. The study protocol was approved by the ethics committee of the Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Written informed consent was obtained from each participant.\n",
      "\n",
      "Dietary intakes\n",
      "\n",
      "Dietary intake was assessed with the use of a valid and reliable, 168-item, semi-quantitative food frequency questionnaire (FFQ), which included a list of foods with standard serving sizes. Based on macronutrient composition and using available literature, 25 food groups were categorized  including different kinds of green, red-yellow, starchy and other vegetables (squash, eggplant, onions, garlic, cabbages, peppers and chilli), fruits (all kinds of fruits and dried fruits), nuts and seeds, legumes, eggs (all kinds of preparations), liquid oils, solid oils (butter and hydrogenated fats), low fat dairy, high fat dairy, whole grains (whole wheat breads, flours and biscuits, barley, wheat, corn and sprouts), refined grains (rice, macaroni, white bread and flours), fast foods (processed meats, fried potato and pizza), soft drinks (all kinds of sugar added beverages), salty snacks (salty biscuits, pickles and chips), red meats, organ meats, fish(all kinds of preparations, tuna fish), poultry (all kinds of preparations), sweets (cakes, donut, biscuits, desserts and chocolates), sweetened fruit juices, sugar (sugar, jam, honey, candy), tea and coffee.\n",
      "\n",
      "Anthropometric measurements and blood pressure\n",
      "\n",
      "While the subjects were minimally clothed and not wearing shoes, weight was measured using digital scales (Seca 707; Hamburg, Germany) and recorded to the nearest 100 g; Height was measured with a tape measure (model 208 Portable Body Meter Measuring Device; Seca) while the subjects were standing with shoulders in normal alignment and not wearing shoes. Body Mass Index (BMI) was calculated. Waist Circumference (WC) was measured at the umbilical level with the use of an upstretched tape measure without any pressure to body surface. Measurements were recorded to the nearest 0.1 cm. Blood Pressure (BP) was measured twice, at least 30-second interval, after the participants sat for 15 min and the mean BP of the 2 measurements recorded was reported as the subject’ s BP.\n",
      "\n",
      "Physical activity\n",
      "\n",
      "Physical activity level was assessed using the Persian translated Modifiable Activity Questionnaire (MAQ) in Tehranian adults, for which high reliability and relatively moderate validity have been reported. The frequency and time spent on light, moderate, hard and very hard intensity activities according to the list of common activities of daily life over the past year were obtained. Physical activity levels were expressed as metabolic equivalent hours per week (METs/h/wk).\n",
      "\n",
      "Laboratory assays\n",
      "\n",
      "Between 7:00 and 9:00 AM, after 12 to 14 hr of overnight fasting, blood samples were drawn into vacutainer tubes in a sitting position from all study participants . Samples were centrifuged within 30 to 45 min of collection according to standard protocols. All biochemical analyses were performed at the TLGS research laboratory on the same day of blood collection, and analyses were conducted using a Selectra 2 autoanalyzer (Vital Scientific, Spankeren, the Netherlands). Fasting Blood Glucose (FBG) was measured by the enzymatic colorimetric method using glucose oxidase. Triglycerides (TG) were measured using TG kits (Pars Azmoon, Tehran, Iran) by enzymatic colorimetric tests and with glycerol phosphate oxidase. HDL-C was measured after precipitation of apolipoprotein B containing lipoproteins with phosphotungstic acid. Monitoring of assay performance was performed once every 20 tests, using lipid control serum, Percinorm (reference range), and Percipath (pathologic range) wherever applicable (Boehringer Mannheim, Germany; catalog no. 1446070 for Percinorm and 171778 for Percipath). Lipid standard (Cfas, Boehringer Mannheim; catalog no. 759350) was used to calibrate the Selectra 2 auto analyzer for each day of laboratory analyses, and all samples were analyzed when internal quality control met the acceptable criteria. Inter- and intra-assay coefficients of variation were both 2.2% for serum glucose and 1.6% and 0.6% for TG, respectively.\n",
      "\n",
      "Genetic analysis\n",
      "\n",
      "For genotyping the APOA1/APOC3 polymorphisms, buffy coats were separated from the non-coagulated whole blood samples and stored at −70 °C until processing, when genomic DNA was extracted by the Proteinase K, salting out method. The Polymerase Chain Reaction followed by Restriction Fragment Length Polymorphism technique (PCR-RFLP) was employed to investigate polymorphisms in the gene fragments .\n",
      "\n",
      "PCR was done using the following primer; APOA1 (rs670, −75G>A and rs5069,+83C>T) (F: 5′-AGG GAC AGA GCT GAT CCTTGA ACT CTT AAG-3′; R: 5′-TTA GGG GCA CCT AGCCCT CAG GAA GAG AGC A-3′)/APOC3 (rs5128, C3238>G) (F:5′-GGT GAC CGA TGG CTT CAG TT-3′; R:5′-CAGAAG GTG GAT AGA GCG CT-3′); hybridization was carried out in a DNA thermal cycler (Corbett co. Australia). Amplified DNA was digested with MspI (HpaII) and SacI restriction enzymes (Fermentas) at 37 °C for overnight ; fragments were separated by electrophoresis on a 2% agarose gel. DNA fragments were visualized by gel documentation (Optigo Co. Optigo, Ijsselstein, The Netherland); 5% of samples were randomly replicated and genotyped with ≥99% concordance. Five percent of the PCR samples were directly sequenced to confirm the PCR-RFLP results.\n",
      "\n",
      "Definitions\n",
      "\n",
      "MetS was defined as participants with three or more of the following conditions by the modified National Cholesterol Education Program/Adult Treatment panel III (ATP III) definition : 1) TG ≥150 mg/dl or drug treatment, 2) Low density lipoprotein cholesterol (LDL-C) <40 mg/dl in men and <50 mg/dl in women or drug treatment; 3) Elevated BP ≥130/85 mmHg or drug treatment for a previous diagnosis of hypertension, and 4) FBG ≥110 mg/dl or drug treatment of hyperglycemia. WC was coded according to the newly-introduced cut-off points for Iranian adults, i.e. ≥95 cm for both genders.\n",
      "\n",
      "Statistical analysis\n",
      "\n",
      "Statistical analyses were performed using the Statistical Package for Social Sciences (Version 16.0; SPSS, Chicago, IL) and STATA (Statistics/Data analysis 12.0). A 2-sided p-value <0.05 was considered significant. Pearson’s chi-square statistic was used to test the Hardy-Weinberg Equilibrium for the SNP and to test the differences in percentages, using Power-Marker software. TG concentration was log-transformed for the statistical analysis. Multiplicative interactions between quartiles of food group intakes and polymorphisms (dominant model) in relation to MetS were examined using conditional logistic regression analysis, after adjustment for baseline BMI and using the likelihood ratio test; a comparison of the likelihood scores of the 2 models with and without the interaction terms. Conditional logistic regression was used to examine the joint role of quartiles of dietary pattern scores and genotypes of rs5128 (CC/CG+GG), rs670 (GG/GA+AA) and rs5069 (CC/CT+TT) in predicting MetS risk, using the lowest quartile of food group in-takes and homozygote group with the major allele as the reference category. For combined analyses, the risk genotypes, which comprised the rs670 (GA+AA) and rs5069 (CT+TT) were included in the analysis. When APOC3 rs5128 was included in the analysis, the risk genotype combination comprised rs670 (GA+AA), rs5069 (CT+TT) and rs5128 (CC). Conditional logistic regression was used to examine the joint role of quartiles of food group intakes and genotype combinations in predicting MetS risk, which were adjusted for baseline BMI. To determine the p-value for trend across the quartiles of food group intakes, logistic regression was used with the median of each quartile of food group intakes used as a continuous variable.\n",
      "\n",
      "Results\n",
      "\n",
      "The mean (SD) age of study participants was 42.1 (12) and 42.4(13) years in cases and controls at baseline, respectively. Cases had higher mean BMI in comparison with controls, 26.1(4) vs. 22.9(4) Kg/m2 (p< 0.05) at baseline. In MetS subjects, the mean (SD) of MetS risk factors were different with controls at baseline; the low HDL-C concentration (78.5%) and abdominal obesity (74.6%) had the highest prevalence among MetS risk factors. There were no statistical differences in the mean energy and macronutrient intakes, depending on MetS status (Table 1).\n",
      "\n",
      "No statistically significant differences were observed in genotype frequencies of APOA1 rs670/rs5069 and APOC3 rs5128 between MetS subjects and controls. Genotype frequency did not deviate from Hardy-Weinberg equilibrium expectations, except for rs670 (Table 2).\n",
      "\n",
      "Adjusted odds ratio for MetS according to quartile classification of food groups by the dominant model of APOA1/APOC3 genotypes are presented in table 3. The risk of MetS was not homogenous in APOA1 rs670 genotypes, across quartiles of sugar and nut group intakes; A allele carriers of rs670 had lower odds of MetS in higher quartiles of sugar group intake (OR: 3.0, 1.60, 1.52, 1.30, P trend<0.01) (P interaction= 0.02), compared to the GG genotype (OR: 1, 1.70, 1.31, 2.20, P trend=0.46). The GG genotype group of rs670 and high nut group intake had the highest MetS risk, compared with minor allele carriers and the low nut group intake (P interaction=0.0006). MetS risk appeared to be significantly increased in higher quartiles of fast food (P trend=0.04) and salty snack (P trend=0.006) group intakes in A (allele carriers of APOA1 rs670). Examination of other food groups did not identify a gene-food group interaction with APOA1 rs670 genotypes (data not shown).\n",
      "\n",
      "There were interactions between APOA1 rs5069 and three food group intakes in relation to MetS risk: for the fish group intake, participants with T allele carriers had higher MetS risk when they had higher intakes of this group (P interaction=0.04). Carriers of CC genotype of rs5069 had lower MetS risk with high tea-coffee intakes, compared to those with lower intakes. There was a decreasing trend of ORs of MetS risk (OR: 1.97, 1.21, 1.11, 0.73, P trend<0.01) in T allele carriers of rs5069 and higher sugar group intakes, compared to the CC genotype (OR: 1, 1.39, 1.04, 1.53, P trend=0.66), (P interaction=0.04). MetS risk appeared to be significantly increased in higher quartiles of salty snack group intake in CC homozygote of APOC3 rs5128 (P trend=0.02). Examination of other food groups did not identify a gene-food group interaction with APOC3 genotypes (data not shown).\n",
      "\n",
      "Adjusted ORs (95% CI) for MetS according to quartile classification of food group intakes by the combined model of APOA1/APOC3 genotypes were shown in table 4. The combined group of APOA1 SNPs (rs670/rs5069) interacted with sugar group intake in determining MetS (P interaction=0.02). The A and T allele carriers (GA+AA/CT+TT) in the highest quartile of sugar group intake had the lowest risk of MetS (OR: 0.23, CI: 0.08–0.64), compared to other combinations and lower sugar intake. A significant interaction between quartiles of the fish group intake and APOA1 combined group was found; the ORs for the A and T allele carriers were (1, 2.80, 2.41, 4.0; P trend=0.20) in quartiles of fish group intake, relative to other combined genotypes (2.60, 3.91, 2.90, 1.82; P trend=0.88) (P interaction=0.03). The combination of APOA1 genotypes did not alter the decreasing trend of MetS risk in quartiles of other food group intakes (data not shown). The combined effect of genotypes of APOC3/APOA1 showed further decrease in MetS risk in higher quartiles of sugar group intakes (OR: 1, 0.24, 0.26, 0.14, P trend=0.001) relative to other combinations (P interaction=0.008). The genotype carriers (GA+AA/CT+TT/CC) in the highest quartile of fish group intake had greater risk of MetS (OR: 6.27, CI: 1.86–21.2), compared to other genotypes. The SNPs×sweet beverage group intake was seen in relation to MetS risk. Carriers of GA+AA/CT+TT/CC genotypes and high intake of sweet beverage group showed further increase in MetS risk (OR: 1, 4.69, 7.62, 9.58, P trend<0.001) relative to other combinations (OR: 2.98, 3.93, 4.07, 4.41, P trend<0.009) (P interaction=0.03). Other food groups did not modulate the association of combined genotype carriers of APOA1 and APOA1/APOC3 in relation to MetS risk.\n",
      "\n",
      "\n",
      "\n",
      "Characteristics of the study population in subjects with metabolic syndrome (MetS) cases and controls: Tehran Lipid and Glucose Study\n",
      "\n",
      "P<0.05;\n",
      "\n",
      "values are mean (SD) unless otherwise listed. BMI: body mass index, WC: waist circumference, BP: blood pressure, HDL-C: high density lipoprotein cholesterol, TG: triglycerides, FBS: fasting blood glucose.\n",
      "\n",
      "BMI≥30 kg/m2,\n",
      "\n",
      "WC≥95 cm for genders,\n",
      "\n",
      "Elevated BP ≥130/85 mmHg,\n",
      "\n",
      "HDLC <40 mg/dl in men and <50 mg/dl in women;\n",
      "\n",
      "TG≥150 mg/dl,\n",
      "\n",
      "High FBG ≥110 mg/dl.\n",
      "\n",
      "Genotype and allele frequency of APOA1 and APOC3 polymorphisms in subjects with metabolic syndrome (MetS) cases and controls: Tehran Lipid and Glucose Study\n",
      "\n",
      "n(%)\n",
      "\n",
      "Adjusted ORs (95% CI) for metabolic syndrome according to quartile classification of food group intakes by dominant model of APOA1/APOC3 genotypes\n",
      "\n",
      "OR: Odds Ratio, Q: Quartile of food group intakes. APOA1: rs670 (−75G>A), rs5069 (+83C>T), APOC3: rs5128 (3238C>G)\n",
      "\n",
      "ORs (95% CI) were calculated by using conditional logistic regression model, adjusted for baseline BMI and energy intake. Participants were joint classified (8 groups) according to quartiles (Q) of food group intakes and dominant model of rs5128, rs670 and rs5069 genotypes. The lowest quartile of food group intakes and homozygote genotype of major allele were used as the reference group.\n",
      "\n",
      "Adjusted OR (95% CI) for metabolic syndrome and combined APOA1/APOC3 genotypes according to quartile classification of food group intakes\n",
      "\n",
      "APOA1: rs670 (−75G>A), rs5069 (+83C>T), APOC3: rs5128 (3238C>G). DP: Dietary pattern, Q: Quartile of food group intakes.\n",
      "\n",
      "ORs (95% CI) were calculated using conditional logistic regression model, adjusted for baseline BMI. Participants were joint classified (8 groups) according to quartiles of food group intakes and risk genotype carriers of rs670 (GA+AA) and rs5069 (CT+TT). The lowest quartile of food group intakes and risk genotype carriers were used as the reference group. When APOC3 rs5128 was included in the analysis, the risk genotype combination comprised rs670 (GA+AA), rs5069 (CT+TT) and rs5128 (CC).\n",
      "\n",
      "Discussion\n",
      "\n",
      "The interaction between food group intakes and genetic variants of APOA1/APOC3 SNP (rs670, rs5069, rs5128) in relation with MetS risk was assessed in the present nested case-control study of Tehranian adults. Intake of sugar was associated with a lower risk of the MetS among the A allele carriers of rs670, T allele carriers of rs5069, the APOA1 combined GA+AA/CT+ TT/CC genotypes. Moreover, subjects with GG genotypes, in the highest quartiles of nuts consumption, in comparison with minor allele carriers with low nuts intake had the highest MetS risk. Sugar-sweet beverages (SSB) intakes interacted with combined APOA1/APOC3 genotypes on MetS risk. Intakes of SSB and fish groups were associated with higher MetS risk among individuals with combined GA+AA/CT+TT/CC genotypes.\n",
      "\n",
      "The association between changes in the SSB consumption and the incidence of the MetS and its components was assessed in a Spanish Mediterranean cohort of university graduates . Participants who increased their consumption of SSB (upper v. lower quintile) after 6 years of follow-up, had a significantly higher risk of developing the MetS (adjusted OR 2.2, 95% CI: 1.4, 3.5; P for trend=0.003); in contrast to this study, the results of another Iranian study are in agreement with those of the current study . Khosravi-Boroujeni et al found no significant association between SSB intake and MetS, a lack of significant associations that persisted even after controlling for potential confounders. In addition to this study, Lutsey et al in a well-designed prospective study also showed that consumption of SSBs was not associated with incident MetS among middle-aged adults . Another study analyzing data from two well-kwon cohorts about SSB and genetic risk of obesity, assessed 32 polymorphisms that are known to be associated with BMI and observed that the higher the SSB intakes, the greater the BMI increase per increment of 10 risk allele .\n",
      "\n",
      "Other studies have shown a direct correlation between sugar intake and risk of metabolic syndrome . One of the reasons that might explain why MetS risk was lower in the A allele carrier across the quartiles of sugar intake in the current study, is this fact that jam consumption has been considered in the definition of sugar group intake. Jams are made from different fruits rich in several antioxidants and polyphenols. Polyphenolic compounds are ubiquitous dietary components, mainly flavonoids and tannins. Specific polyphenols, effective in scavenging reactive oxygen and reactive nitrogen species, are able to modulate genes associated with metabolism, stress defense, drug metabolizing enzymes, and detoxification and transporter proteins. Their overall effect is protective in overcoming damaging effects of chronic diseases such as MetS . As mentioned above, another finding of the present study showed that consumption of nuts is related to MetS risk. Nuts as a whole are healthy foods because of their good fatty acid profile (low in saturated fats and high in mono- and polyunsaturated fats (MUFA and PUFA, respectively)) and low available carbohydrate content, as well as being good sources of vegetable protein, fiber, phytosterols, polyphenols, vitamins and minerals; nuts may therefore be a useful component of a dietary strategy aimed at improving the risk factors of the MetS, diabetes and CVD . Many studies have shown that nuts intake can improve glycemic control  and reduce serum LDL-C . It is possible that the beneficial effect of nuts on serum lipids and glucose may depend on the level of MUFA; however if the salty nuts are consumed, they can cause health risks such as increased blood pressure. Given that most of Iranian people consume nuts in the salty roasted form, it can be expected that the benefits of nuts consumption are covered by high intake of salt. On the other hand, nuts contain high energy density and high intakes of it may lead to overweight and obesity, which in turn, pave the way for the development of hypertension, hyperlipidemia and other risk factors of MetS.\n",
      "\n",
      "Although interaction of APOA1 genotypes (rs670) and APOC3 (rs5128) with salty snacks and of APOA1 genotypes (rs670) with fast food were not significant, the increasing trend in consumption of these food groups was seen in subjects carrying the A and T alleles of ApoA1 and the CC homozygote of the APOC3 polymorphism. Fast foods have a high amount of saturated fat and trans-fatty acid, energy density, glycemic index, sodium, refined carbohydrate and therefore poor diet quality. Besides these negative points, the low dietary phytochemical index and total antioxidant capacity of mentioned food, fast foods have become one of the most important risk factors of MetS.\n",
      "\n",
      "Some studies showed that carriers of the A allele were more responsive to changes in dietary fat than were GG subjects . Results of one study  examining the effect of fast food intake on the risk of MetS were consistent with those of the present study, and showed that after adjustment for all potential confounding variables, the risk of MetS, in the highest quartile of fast foods compared with the lowest, was 1.85 (95% CI:1.17–2.95). In the Qi et al’s study, interaction of fried food consumption with genetic risk in relation to BMI was assessed on 9623 women from the Nurses’ Health Study and 6379 men from the Health Professionals Follow-up Study. Interaction between fried food consumption and a genetic risk score was observed based on 32 BMI-associated variants in both the Nurses’ Health Study and Health Professionals Follow-up Study (p≤0.001 for interaction) .\n",
      "\n",
      "Regarding the interaction of salty snack consumption and APOA1 genotype on MetS risk, it should be said that salty snack because of the high levels of salt can increase blood pressure over time. Although it is not clear how the mutant allele affects MetS risk, future studies are recommended to clarify the molecular mechanisms underlying these gene-nutrients interactions.\n",
      "\n",
      "Participants with higher consumption of fish had a high risk of MetS, if they were the carriers of the T allele. Unlike many studies which show protective role of fish consumption on MetS risk, some studies demonstrated no association between fish consumption and risk of MetS . Fish preparation methods (e.g., frying) and certain contaminants in fish may attenuate the potential and beneficial effects of fish consumption. Since most Iranian people eat deep-fried fish, this may limit the protective effect of fish consumption on MetS, not seen in this population. In subjects with the major homozygote of APOA1 rs5069, higher quartiles of tea and coffee consumption were associated with a lower risk of MetS, compared with minor allele carriers. Coffee is among the most widely consumed beverages in the world , the consumption of coffee has been known to decrease the risk of type 2 diabetes . The favorite beverage of Iranians is tea, whereas coffee is not very common. Tea and coffee are important dietary sources of polyphenols (flavonols and catechins); because of high content of catechins (epicatechin, epicatechin gallate, epigallocatechin and epigallocat-echin gallate), also known as tea flavonoids, it may be assumed that the habitual consumption of tea seems to protect against the development of cardiovascular disease and inversely is associated with metabolic syndrome. Furthermore, several in vitro and in vivo studies have tried to elucidate the role of these beverages and a large amount of experimental studies clearly indicate beneficial effects of polyphenols on coronary artery disease. Moreover, the growing number of studies suggest that coffee consumption is associated with lower blood pressure , lower blood glucose  and lower triglycerides .\n",
      "\n",
      "The main strength of the present study was its longitudinal design and the use of appropriate number of cases and matched controls from all demographic strata, and our results also emphasized the importance of taking into account the gene-diet interaction effect in association studies. Excluding subjects who created changes in dietary pattern because of having MetS was the strength of this study. Evaluation of dietary intake at just one time point was one of the limitations. However, assessing dietary intake by FFQ in about one year before developing MetS can cover this limitation. The second limitation was the lack of measurement of insulin sensitivity as a sensitive marker of MetS. For this reason, the present study did not detect any interaction between food groups and genotypes in relation to it. Another limitation of this study was considering the limited number of polymorphisms in the analysis of the interaction between dietary patterns and polymorphism in association with MetS that most polymorphisms in relation to the components of MetS do not cover. The small effect size of polymorphisms reduced the probability of observing a significant correlation. Future studies should investigate the genetic basis of individuals namely the cumulative effect of polymorphisms involved in the desired outcome and calculate their genetic risk score. Due to the limited sample size, there was no possibility of gender segregation in the analyses. Although lifestyle factors such as smoking, physical activity, education levels were considered in this study, inevitably some other confounding factors were not measured.\n",
      "\n",
      "Conclusion\n",
      "\n",
      "In conclusion, this study provides evidence that some food groups modulate the effect of APOA1 and APOC3 SNPs in relation to MetS risk; being A and T allele carriers of APOA1 (rs670, rs5069) and C allele carriers of APOC3 (rs5128) further increased MetS risk in individuals with higher consumption of sweet beverages and fish groups. Also, A and T alleles of APOA1 appear to be protective for MetS risk in participants with higher scores of the sugar group intake.\n",
      "\n",
      "Conflict of Interest\n",
      "None of the authors has any conflict of interest to declare.\n"
     ]
    }
   ],
   "source": [
    "print(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "5a56d84e-1a79-480f-ae76-addaab3ce9e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('PMC5410135_pubmed_parser.txt', 'w') as f:\n",
    "    f.write(text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "11c612ba-084e-4d7e-917b-9e7e34296d78",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "TF",
   "language": "python",
   "name": "tf"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
